Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
0 hedge funds and large institutions have $0 invested in Array Biopharma Inc in 2019 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $159K → $0 (-$159K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$159K |
ARRY Hedge Fund Activity: Q4 2019 in Review
0 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2019, worth a combined $0 — down 100% from $159K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ARRY and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Advisory Services Network, exiting entirely with an estimated $159K sold.
- 0 institutional investors held Array Biopharma Inc (ARRY) as of Q4 2019, down from 1 in Q3 2019.
- Funds reported $0 of Array Biopharma Inc stock for Q4 2019, down 100% quarter-over-quarter.
- 0 funds opened new Array Biopharma Inc positions in Q4 2019 and 1 closed out, a net change of -1 holder.
- The largest Array Biopharma Inc seller in Q4 2019 was Advisory Services Network, an estimated $159K sold.
Based on aggregated 13F filings for Q4 2019.